AEterna Zentaris Inc. (AEZS) Short Interest Update
AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 1,920,407 shares, a growth of 121.9% from the July 14th total of 865,410 shares. Based on an average daily trading volume, of 12,000,600 shares, the short-interest ratio is presently 0.2 days. Approximately 19.4% of the company’s stock are short sold.
Several brokerages have recently weighed in on AEZS. Maxim Group set a $4.00 target price on AEterna Zentaris and gave the stock a “buy” rating in a research report on Friday. Zacks Investment Research raised AEterna Zentaris from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, HC Wainwright set a $3.00 target price on AEterna Zentaris and gave the stock a “buy” rating in a research report on Wednesday, July 5th.
AEterna Zentaris (NASDAQ AEZS) opened at 2.04 on Friday. AEterna Zentaris has a 1-year low of $0.78 and a 1-year high of $5.59. The company has a 50 day moving average price of $1.56 and a 200 day moving average price of $2.08. The firm’s market cap is $29.24 million.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.05. AEterna Zentaris had a negative return on equity of 502.76% and a negative net margin of 1,945.78%. The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.22 million. AEterna Zentaris’s revenue was up 153.1% compared to the same quarter last year. On average, equities research analysts forecast that AEterna Zentaris will post ($1.36) earnings per share for the current year.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.